Top Markets
#1 Electroneum Electroneum +15.55%
#2 Status Status +13.74%
#3 Infinity Ground Infinity Ground +11.65%
#4 Ski Mask Dog Ski Mask Dog +8.30%
#5 City Boy City Boy +7.12%
#6 TG.Casino TG.Casino +6.50%
#7 Thena Thena +5.32%
#8 Akash Network Akash Network +4.79%
#9 The Grays Currency The Grays Currency +4.63%
#10 Bitway Bitway +4.58%
Coin of the day
Electroneum Electroneum
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classement en actions #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Prix de l'action
$451.59
Capitalisation boursière
$114.70B
Changement (1 jour)
-2.36%
Changement (1 an)
-11.89%
Pays
US
Échange Vertex Pharmaceuticals Incorporated (VRTX)

Catégorie

Healthcare
Revenus pour Vertex Pharmaceuticals Incorporated (VRTX)
Revenus en Dec 2025 TTM : $12.04B
Selon les derniers rapports financiers de Vertex Pharmaceuticals Incorporated, le chiffre d'affaires actuel de l'entreprise (TTM) est de $12.04B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $11.02B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $9.87B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Vertex Pharmaceuticals Incorporated de 2000 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $12.04B 0.31%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 302.35%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 19.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -24.56%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 30.38%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -54.39%
NL